Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intellectual Property Law

This article was originally published in RAJ Devices

Executive Summary

Russian president signs new law to strengthen IP protection

You may also be interested in...



Torrent Outlook Muted On COVID-19, Regulatory Concerns

After a tepid performance in the fiscal fourth quarter, Torrent expects its key markets India, US and Brazil to be impacted the COVID-19 fallout as well as a lack of visibility on regulatory approvals for its manufacturing facilities.

QUOTED. 28 May 2020. Ryan Walters.

Biotronik recently hired its first-ever chief medical officer, former Mayo Clinic medical director David Hayes, as part of a bid to deepen the Berlin-based firm’s relationships in the US. Here’s what company president Ryan Walters said about the American market.

‘Business Unusual’: COVID-19 Brought Commercial Changes To Pharma And It May Stick

The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel